MedPath

JOHNSON & JOHNSON PHARMACEUTICAL RESEARCH & DEVELOPMET L.L.C.

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website

A Study of the Pharmacokinetics of ER OROS Paliperidone in Volunteers With Normal or Impaired Renal Function

Phase 1
Completed
Conditions
Renal Impairment
Schizophrenia
First Posted Date
2008-11-14
Last Posted Date
2011-06-13
Lead Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Target Recruit Count
47
Registration Number
NCT00791401

A Study of the Safety and Effectiveness of Rabeprazole for the Treatment of Gastroesophageal Reflux Disease (GERD) in Pediatric Patients

Phase 3
Completed
Conditions
Gastroesophageal Reflux Disease (GERD)
Interventions
First Posted Date
2008-11-10
Last Posted Date
2013-01-24
Lead Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Target Recruit Count
127
Registration Number
NCT00787891

A Study to Assess the Potential Effects of a Single-Dose Administration of Trabectedin on the QT Intervals of the Electrocardiogram

Phase 2
Completed
Conditions
Solid Tumor
Interventions
Drug: Placebo
First Posted Date
2008-11-06
Last Posted Date
2014-04-11
Lead Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Target Recruit Count
76
Registration Number
NCT00786838

Bioequivalence Study of Patches With Different Equilibration Profiles

Phase 1
Completed
Conditions
Female Contraception
First Posted Date
2008-10-17
Last Posted Date
2011-06-08
Lead Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Target Recruit Count
42
Registration Number
NCT00775086

Study Evaluating and Comparing Single Dose and Multiple Dose Pharmacokinetics of ER OROS Paliperidone in Healthy Japanese and Caucasian Adults.

Phase 1
Completed
Conditions
Schizophrenia
First Posted Date
2008-09-23
Last Posted Date
2011-06-08
Lead Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Target Recruit Count
60
Registration Number
NCT00758030

A Drug Interaction Study of the Pharmacokinetics of Topiramate and FLUNARIZINE When Given Together or Separately

Phase 1
Completed
Conditions
Human Volunteers
Migraine
First Posted Date
2008-09-15
Last Posted Date
2011-05-18
Lead Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Target Recruit Count
75
Registration Number
NCT00752466

Efficacy and Safety of Tapentadol Extended Release Tablets in the Treatment of Moderate to Severe Pain in Subjects With Knee Osteoarthritis

Phase 2
Completed
Conditions
Osteoarthitis
Chronic Pain
Knee Pain
First Posted Date
2008-09-01
Last Posted Date
2011-05-18
Lead Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Target Recruit Count
670
Registration Number
NCT00745069
© Copyright 2025. All Rights Reserved by MedPath